| Today's Top Story |  |  | |  | Get More with The Business Platinum Card from American Express OPEN. EARN 25,000 MEMBERSHIP REWARDS® POINTS by spending $5,000 in the first 3 months of Card membership†.
PLUS GET 40+ PREMIUM BENEFITS:
• Complimentary Airport Club Access
• Annual $200 Airline Fee Credit for any Airline
• 24/7 personal concierge
LEARN MORE †Terms and Restrictions Apply. |
  | Health Care & Policy | | | | - CVR buyback indicates Sanofi's growing confidence in Lemtrada
Sanofi plans to repurchase as much as $152 million worth of outstanding contingent-value rights related to the success of drugs developed by Genzyme, which it acquired last year. The plan is a sign of Sanofi's increasing confidence in multiple sclerosis drug Lemtrada, or alemtuzumab, which is waiting for regulatory approval and could enter the market next year. Reuters (9/4)       - Biokine licenses leukemia drug candidate to BioLineRX
Biokine Therapeutics granted BioLineRx exclusive worldwide rights to BL-8040, a therapeutic peptide for acute myeloid leukemia and other hematologic cancers. As part of the licensing deal, Biokine will receive $50,000 to $100,000 a month in exchange for certain development services and $250,000 in potential milestone fees plus royalties if the drug is sublicensed to a third party. BioLineRx plans to initiate a midstage trial next year to assess the efficacy of the peptide in AML patients. Genetic Engineering & Biotechnology News (9/4) - ImmusanT's celiac vaccine Nexvax2 enters early-stage development
ImmusanT initiated two early-stage trials of Nexvax2, a celiac disease vaccine designed to help patients develop tolerance to gluten, which damages the lining of their small intestines. One trial, conducted in Australia and New Zealand, will evaluate tolerability, safety and pharmacokinetics in patients on a gluten-free diet. The other study is in the U.S. Mass High Tech (Boston) (9/4) - Neural stem cells help return sensation to patients with paralysis
Swiss researchers are testing the use of neural stem cells in the treatment of three patients with broken spines. After six months, two of the patients reported sensations of touch and heat between the chest and belly button, according to the findings presented at a spinal cord society meeting. Nine more patients are set to receive the treatment. New Scientist (9/3) - Collaborative study will look at circulating tumor cells
NYU Langone Medical Center and Transgenomic will collaborate on research to detect mutations in circulating tumor cells of patients with early-stage lung cancer in an effort to personalize treatment. Researchers will compare the genetic profiles of cell-free DNA with CTC DNA to provide new insights into the genetic makeup of metastasizing tumor cells and to identify mutations known to respond to treatment. Genetic Engineering & Biotechnology News (9/4)  |
Built for a new generation of healthcare executives, the online MS in Health Care Administration at Saint Joseph's University offers a research-based curriculum delivered by professors with real-world experience from every corner of the healthcare industry. Specializations available in Health Care Ethics or Informatics. |
| Food & Agriculture | | | | | Industrial & Environmental | | | | - BIO, 6 groups move to intervene in RFS lawsuit
BIO and six other groups are seeking to intervene in a lawsuit brought by an oil-industry group against the 2012 cellulosic and advanced biofuel targets under the Renewable Fuel Standard. In a brief filed Tuesday, the groups said the Environmental Protection Agency's 2012 cellulosic and advance biofuels targets are based on market projections and in keeping with rules set by Congress. "Precedent makes clear that EPA can adopt standards calculated to spur development, consistent with Congress's express statutory objectives," the groups' filing showed. DomesticFuel.com (9/4)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | Winning can be defined as the science of being totally prepared."
--George Allen,
American football coach  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, September 04, 2012
- Friday, August 31, 2012
- Thursday, August 30, 2012
- Wednesday, August 29, 2012
- Tuesday, August 28, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment